Notably, the FGFR3-TACC3 fusions recurrent in urothelial bladder carcinoma, glioblastoma (GBM), head–neck squamous cell carcinoma (HNSC), and low-grade glioma show stable and minor response to FGFR inhibitor treatment19,78. This evidence concerns the gene FGFR3 and glioma.